Biopharmaceutical company Telix Pharmaceuticals Limited (ASX: TLX) (NASDAQ: TLX) announced on Wednesday that its Telix Manufacturing Solutions (TMS) facility in Brussels South (Seneffe), Belgium has completed the first commercial delivery of Good Manufacturing Practice (GMP)-grade radiopharmaceutical doses.

The initial shipment was supplied to the AIRC hospital collaboration in Charleroi, Belgium.

TMS Brussels South spans 2,800 square metres and ranks among Europe's largest radiopharmaceutical production sites, featuring nine GMP manufacturing lines, clean rooms, a radiopharmacy and two cyclotrons. The facility also hosts significant research and development capabilities, with a focus on alpha-emitting isotopes.

Telix Pharmaceuticals is headquartered in Melbourne and has operations across the US, Brazil, Canada, Europe and Japan. The company specialises in therapeutic and diagnostic radiopharmaceuticals targeting oncology and rare diseases.